123 related articles for article (PubMed ID: 38554443)
1. PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration.
Zieliński M; Sakowska J; Iwaszkiewicz-Grześ D; Gliwiński M; Hennig M; Żalińska M; Wołoszyn-Durkiewicz A; Jaźwińska-Curyłło A; Kamińska H; Owczuk R; Młynarski W; Jarosz-Chobot P; Bossowski A; Szadkowska A; Fendler W; Beń-Skowronek I; Chobot A; Myśliwiec M; Siebert J; Marek-Trzonkowska N; Trzonkowski P
Int Immunopharmacol; 2024 May; 132():111919. PubMed ID: 38554443
[TBL] [Abstract][Full Text] [Related]
2. Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients.
Pellegrino M; Crinò A; Rosado MM; Fierabracci A
PLoS One; 2019; 14(1):e0210839. PubMed ID: 30650147
[TBL] [Abstract][Full Text] [Related]
3. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
4. PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes.
Li X; Zhong T; Tang R; Wu C; Xie Y; Liu F; Zhou Z
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32236416
[TBL] [Abstract][Full Text] [Related]
5. Human Endothelial Cells Modulate CD4
Lim WC; Olding M; Healy E; Millar TM
Front Immunol; 2018; 9():565. PubMed ID: 29628925
[TBL] [Abstract][Full Text] [Related]
6. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
Front Immunol; 2019; 10():2606. PubMed ID: 31781109
[TBL] [Abstract][Full Text] [Related]
7. Isolation and enrichment of mouse insulin-specific CD4
Đedović N; Paunović V; Stojanović I
J Immunol Methods; 2019 Jul; 470():46-54. PubMed ID: 31039339
[TBL] [Abstract][Full Text] [Related]
8. FOXP3+Helios+ Regulatory T Cells, Immune Activation, and Advancing Disease in HIV-Infected Children.
Khaitan A; Kravietz A; Mwamzuka M; Marshed F; Ilmet T; Said S; Ahmed A; Borkowsky W; Unutmaz D
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):474-84. PubMed ID: 27003495
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
10. Human CD8
Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
Front Immunol; 2018; 9():2788. PubMed ID: 30555473
[TBL] [Abstract][Full Text] [Related]
11. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
[TBL] [Abstract][Full Text] [Related]
14. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
15. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
Woods DM; Ramakrishnan R; Laino AS; Berglund A; Walton K; Betts BC; Weber JS
Clin Cancer Res; 2018 Dec; 24(24):6236-6247. PubMed ID: 30131384
[TBL] [Abstract][Full Text] [Related]
16. Reduced PD-1 expression on circulating follicular and conventional FOXP3
Vecchione A; Di Fonte R; Gerosa J; Jofra T; Cicalese MP; Napoleone V; Ippolito E; Galvani G; Ragogna F; Stabilini A; Bianconi E; Grogan P; Bonura C; Bonfanti R; Frontino G; Nano R; Melzi R; De Pellegrin M; Laurenzi A; Meschi F; Barera G; Rigamonti A; Indirli R; Bosi E; Piemonti L; Aiuti A; Battaglia M; Fousteri G
Clin Immunol; 2020 Feb; 211():108319. PubMed ID: 31794865
[TBL] [Abstract][Full Text] [Related]
17. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
18. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
[TBL] [Abstract][Full Text] [Related]
19. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
